AMENDMENTS TO THE CLAIMS

1. (Currently amended) ~~Use of the compounds of the general~~ A method of treating a disease, damage or disorder of the central nervous system associated with a disorder of neurochemical equilibrium of a biogenic amine or other neurotransmitter, comprising administering to a subject in need thereof a compound of formula **I**



I

wherein

X ~~means~~ is selected from the group consisting of CH_2, ~~or a heteroatom selected from the group consisting of~~ O, S, S(=O), S(=O)$_2$ and NR^a, wherein R^a is selected from the group consisting of hydrogen, ~~or a substituent selected from the group consisting of~~ C_1-C_3-alkyl, C_1-C_3-alkanoyl, C_1-C_7-alkoxycarbonyl, C_7-C_{10}-arylmethoxycarbonyl, C_7-C_{10}-aroyl, C_7-C_{10}-arylalkyl, C_3-C_7-alkylsilyl and C_5-C_{10}-alkylsilylalkoxyalkyl;

Y and Z are each independently ~~from each other mean one or more identical or different substituents linked to any available carbon atom~~ selected from the group consisting of hydrogen, halogen, C_1-C_4-alkyl, C_2-C_4-alkenyl, C_2-C_4-~~alkinyl~~alkynyl, halo-C_1-C_4-alkyl, hydroxy, C_1-C_4-alkoxy, trifluoromethoxy, C_1-C_4-alkanoyl, amino, amino-C_1-C_4-alkyl, *N*-(C_1-C_4-alkyl)amino, *N,N*-di(C_1-C_4-alkyl)amino, thiol, C_1-C_4-alkylthio, sulfonyl, C_1-C_4-alkylsulfonyl, sulfinyl, C_1-C_4-alkylsulfinyl, carboxy, C_1-C_4-alkoxycarbonyl, cyano and nitro;

R^1 ~~means~~ is selected from the group consisting of hydrogen, halogen, C_1-C_7-alkyl optionally substituted with one~~, two, three~~ or more substituents selected from the group consisting of halogen ~~atom~~, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, N-(C_1-C_4) alkylamino, N,N-

di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl and C_1-C_4 alkylsulfinyl; C_2-C_7-alkenyl optionally substituted with one~~, two, three~~ or more halogen atoms; C_2-C_7-~~alkinyl~~alkynyl; ~~monocyclic or bicyclic aryl group having from 6 to 10 carbon atoms and altering double bond and said group can be optionally substituted with one or two substituents selected from the group consisting of fluoro, chloro, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4 alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, C_1-C_4 alkylsulfinyl and can be linked to the rest of the molecule by any available carbon atom via direct bond or via C_1-C_4 alkylene group; monocyclic or bicyclic heteroaryl having the meaning of aromatic and partially aromatic groups of a monocyclic or bicyclic ring with 4 to 12 carbon atoms and at least one of them being heteroatom selected from the group consisting of O, S and N wherein available carbon or nitrogen represent the binding site of the group to the rest of the molecule either via direct bond or via C_1-C_4 alkylene group and where said heteroaryl can be optionally substituted with fluoro, chloro, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4 alkyl) amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, C_1-C_4 alkylsulfinyl; five member or six member fully saturated or partly unsaturated heterocycle group containing at least one hetero atom selected from the group consisting of O, S and N wherein available carbon or nitrogen represent the binding site of the group to the rest of the molecule either via direct bond or via C_1-C_4 alkylene group and where said heterocycle can be optionally substituted with fluoro, chloro, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4 alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, C_1-C_4 alkylsulfinyl;~~ hydroxy; hydroxy-C_2-C_7-alkenyl; hydroxy-C_2-C_7-~~alkinyl~~alkynyl; C_1-C_7-alkoxy; thiol; thio-C_2-C_7-alkenyl; thio-C_2-C_7-~~alkinyl~~alkynyl; C_1-C_7-alkylthio; amino-C_2-C_7-alkenyl; amino-C_2-C_7-~~alkinyl~~alkynyl; amino-C_1-C_7-alkoxy; C_1-C_7-alkanoyl; C_7-C_{10}-aroyl; oxo-C_1-C_7-alkyl; C_1-C_7-alkanoyloxy; carboxy; ~~an~~ C_1-C_7-alkyloxycarbonyl; C_1-C_7 ~~or~~ aryloxycarbonyl; carbamoyl; *N*-(C_1-C_7-alkyl)carbamoyl; *N,N*-di(C_1-C_7-alkyl)carbamoyl; cyano; cyano-C_1-C_7-alkyl; sulfonyl; C_1-C_7-alkylsulfonyl; sulfinyl; C_1-C_7-alkylsulfinyl; nitro;

~~or~~ a substituent of the formula **II**:



II

wherein

R^2 and R^3 ~~simultaneously or~~ are each independently ~~from each other have the meaning of~~ selected from the group consisting of hydrogen, C_1-C_4-alkyl, and aryl ~~having the meaning of an aromatic ring as well as fused aromatic rings containing one ring with at least 6 carbon atoms or two rings with totally 10 carbon atoms and with alternating double bonds between carbon atoms~~; or

R^2 and R^3 taken together with [[N]] the nitrogen atom to which they are attached form a ~~have the meaning of~~ heterocycle or heteroaryl group ~~wherein heterocycle relates to five membere or six membere fully saturated or partly unsaturated heterocycle group containing at least one hetero atom selected from the group consisting of O, S and N and where said heterocycle can be~~ optionally substituted with one or two substituents ~~which are~~ selected from the group consisting of halogen, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, and C_1-C_4 alkylsulfinyl; ~~and wherein heteroaryl relates to aromatic and partially aromatic groups of a monocyclic or bicyclic ring with 4 to 12 carbon atoms and at least one of them being heteroatom selected from the group consisting of O, S and N and where said heteroaryl can be optionally substituted with one or two substituents which are selected from halogen, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino , *N,N*-di(C_1-C_4-alkyl) amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, C_1-C_4 alkylsulfinyl~~;

m ~~has the meaning of~~ is an integer from 1 to 3;

n ~~has the meaning of~~ is an integer from 0 to 3;

Q_1 and Q_2 are each independently selected from the group consisting of ~~from each other have the meaning of~~ oxygen, sulfur, ~~or a group:~~




and


wherein ~~substituents~~

y_1 and y_2 are each independently ~~from each other have the meaning of~~ selected from the group consisting of hydrogen, halogen, ~~optionally substituted~~ C_1-C_4-alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl and C_1-C_4 alkylsulfinyl; ~~or~~ aryl optionally substituted with one or two substituents selected from the group consisting of halogen, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl, and C_1-C_4 alkylsulfinyl; ~~wherein an optionally substituted alkyl or aryl have the meaning as defined above,~~ hydroxy, C_1-C_4-alkoxy, C_1-C_4-alkanoyl, thiol, C_1-C_4-alkylthio, sulfonyl, C_1-C_4-alkylsulfonyl, sulfinyl, C_1-C_4-alkylsulfinyl, cyano, and nitro, or

y_1 and y_2 taken together with the carbon atom to which they are attached form a carbonyl group or an imino group;

a monocyclic or bicyclic aryl group; a monocyclic or bicyclic heteroaryl group; and a heterocycle, wherein the monocyclic or bicyclic aryl group, the monocyclic or bicyclic heteroaryl group and the heterocycle are linked to the thiophene ring via a direct bond or a C_1-C_4 alkylene group , and are each optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl and C_1-C_4 alkylsulfinyl;

and ~~of their~~ a pharmaceutically acceptable salt or solvate thereof ~~salts and solvates for the manufacture of pharmaceutical formulations for the treatment and prevention of diseases,~~

~~damages and disorders of the central nervous system caused by disorders of neurochemical equilibrium of biogenic amines or other neurotransmitters~~.

2. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the ~~selected~~ biogenic ~~amines are~~ amine is serotonin, norepinephrine ~~and~~ or dopamine.

3. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the neurotransmitter is glutamate.

4. (Currently amended) ~~Use according to claims 1, 2 or 3~~ The method of claim 1 wherein the ~~compounds~~ compound of ~~the general~~ formula **I** ~~act upon the neurochemical equilibrium by regulating~~ regulates the synthesis, storage, release, metabolism, ~~storing, releasing, metabolizing and/or~~ reabsorption or receptor binding of a biogenic amine ~~amines~~ or neurotransmitter ~~neurotransmitters and binding to their receptors~~.

5. (Currently amended) ~~Use according to~~ The method of claim 4, wherein the ~~compounds~~ compound of ~~the general~~ formula **I** ~~show binding affinity~~ binds to a receptor of ~~one or more~~ a biogenic ~~amines~~ amine.

6. (Currently amended) ~~Use according to~~ The method of claim 5, wherein the ~~compounds~~ compound of ~~the general~~ formula I ~~show a significant binding affinity~~ binds to a serotonin 5-HT_{2A} ~~and~~ or 5-HT_{2C} ~~receptors~~ receptor.

7. (Currently amended) ~~Use according to~~ The method of claim 6, wherein the ~~compounds~~ compound of ~~the general~~ formula I ~~show binding affinity to selected~~ binds to a serotonin 5-HT_{2A} or 5-HT_{2C} ~~receptors~~ receptor with an ~~in a concentration of~~ IC_{50}~~<1μM~~ of less than 1μM.

8. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the ~~compounds~~ compound of ~~the general~~ formula I ~~act as~~ binds to a σ1 receptor ~~ligands in a concentration of~~ with an IC_{50}~~<1μM~~ of less than 1 μM ~~by modulating central neurotransmitter system~~.

9. (Currently amended) ~~Use according to claims 1, 6 or 8~~ The method of claim 1, wherein the c~~ompounds~~ compound of ~~the general~~ formula I ~~show dual binding affinity~~ binds to a σ1 receptor and to at least one serotonin receptor selected from 5-HT_{2A} and 5-HT_{2C}.

10. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the ~~diseases and disorders~~ disease or disorder of the central nervous system ~~are~~ is selected from the group consisting of anxiety, depression ~~and modest depression~~, bipolar disorders, sleeping disorders, sexual disorders, psychosis, borderline psychosis, schizophrenia, migraine, personality disorders, ~~and~~ obsessive-compulsive disorders, social phobia, ~~or~~ panic attacks, organic mental disorders in children, aggression, memory disorders, ~~and~~ personality disorders in elderly people, addiction, obesity, bulimia and ~~similar~~ other eating disorders, snoring, and premenstrual troubles.

11. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the ~~damages of~~ damage to the central nervous system ~~are~~ is caused by trauma, brain stroke, neurodegenerative diseases, cardiovascular disorders ~~such as high blood pressure~~, thrombosis, infarct ~~as well as by~~ or gastrointestinal disorders.

12. (Currently amended) ~~Use according to~~ The method of claim 1 wherein X ~~represents~~ is O, S, or NR^a, wherein R^a is hydrogen, ~~or substituent selected from the group consisting of~~ C_1-C_3-alkyl, C_1-C_3-alkanoyl, C_7-C_{10}-aroyl ~~and~~ or C_7-C_{10}-arylalkyl.

13. (Currently amended) ~~Use according to claims 1 or 12~~ wherein Y and Z are each independently ~~from each other mean one or more identical or different substituents linked to any available carbon atom~~ selected from the group consisting of hydrogen, fluorine, chlorine, bromine, C_1-C_4-alkyl, halo-C_1-C_4-alkyl, hydroxy, C_1-C_4-alkoxy, trifluoromethoxy, C_1-C_4-alkanoyl, amino, amino-C_1-C_4-alkyl, *N*-(C_1-C_4-alkyl)amino, *N,N*-di(C_1-C_4-alkyl)amino, thiol, C_1-C_4-alkylthio, cyano and nitro.

14. (Currently amended) ~~Use according to claims 1, 12 or 13~~ The method of claim 1, wherein R^1 ~~has the maning of~~ is selected from the group consisting of hydrogen, halogen, C_1-C_4-alkyl optionally substituted with one~~, two, three~~ or more substituents selected from the group

consisting of halogen ~~atom~~, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino and *N,N*-di(C_1-C_4-alkyl)-amino; ~~monocyclic or bicyclic aryl group having from 6 to 10 carbon atoms and altering double bond and said group can be optionally substituted with one or two substituents selected from the group consisting of fluoro, chloro, C_1-C_4-alkyl, cyano, nitro, hydroxy, C_1-C_4-alkoxy, thiol, C_1-C_4-alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl) amino, sulfonyl, C_1-C_4-alkylsulfonyl, sulfinyl, C_1-C_4-alkylsulfinyl and can be linked to the rest of the molecule by any available carbon atom via direct bond or via C_1-C_4-alkylene group; monocyclic or bicyclic heteroaryl having the meaning of aromatic and partially aromatic groups of a monocyclic or bicyclic ring with 4 to 12 carbon atoms and at least one of them being heteroatom selected from the group consisting of O, S and N wherein available carbon or nitrogen represent the binding site of the group to the rest of the molecule either via direct bond or via C_1-C_4-alkylene group and where said heteroaryl can be optionally substituted with fluoro, chloro, C_1-C_4-alkyl, cyano, nitro, hydroxy, C_1-C_4-alkoxy, thiol, C_1-C_4-alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl) amino, sulfonyl, C_1-C_4-alkylsulfonyl, sulfinyl, C_1-C_4-alkylsulfinyl; five-member or six-member fully saturated or partly unsaturated heterocycle group containing at least one hetero atom selected from the group consisting of O, S and N wherein available carbon or nitrogen represent the binding site of the group to the rest of the molecule either via direct bond or via C_1-C_4-alkylene group and where said heterocycle can be optionally substituted with fluoro, chloro, C_1-C_4-alkyl, cyano, nitro, hydroxy, C_1-C_4-alkoxy, thiol, C_1-C_4-alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4-alkylsulfonyl, sulfinyl, C_1-C_4-alkylsulfinyl;~~ hydroxyl; C_1-C_4 alkoxy; thiol; C_1-C_4 alkylthio; C_1-C_3 alkanoyl; C_7-C_{10}-aroyl; C_1-C_7 alkanoyloxy, C_1-C_7 alkyloxycarbonyl; C_7-C_{10}-aryloxycarbonyl, carbamoyl, *N*-(C_1-C_7-alkyl)carbamoyl, *N,N*-di(C_1-C_7-alkyl)carbamoyl, cyano, cyano-C_1-C_7 alkyl, nitro;

~~or~~ a substituent ~~represented with~~ <u>of</u> the formula **II**:



II

wherein

R^2 and R^3 ~~simultaneously or~~ are each independently ~~from each other have the meaning of~~ hydrogen, C_1-C_4-alkyl, or aryl; ~~wherein aryl has the meaning as defined above~~ or

R^2 and R^3 taken together with [[N]] with the nitrogen atom to which they are attached form a ~~have the meaning of~~ heterocycle or heteroaryl group selected from the group consisting of morpholine-4-yl, piperidine-1-yl, pyrrolidine-1-yl, imidazole-1-yl and piperazine-1-yl;

m ~~has the meaning of~~ is an integer from 1 to 3;

n ~~has the meaning of~~ is an integer from 0 to 3; and

Q_1 and Q_2 are each independently ~~from each other have the meaning of~~ oxygen or CH_2 ~~group~~

a monocyclic or bicyclic aryl group; a monocyclic or bicyclic heteroaryl group; and a heterocycle, wherein the monocyclic or bicyclic aryl group, the monocyclic or bicyclic heteroaryl group and the heterocycle are linked to the thiophene ring via a direct bond or a C_1-C_4 alkylene group , and are each optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, C_1-C_4 alkyl, cyano, nitro, hydroxy, C_1-C_4 alkoxy, thiol, C_1-C_4 alkylthio, amino, *N*-(C_1-C_4) alkylamino, *N,N*-di(C_1-C_4-alkyl)-amino, sulfonyl, C_1-C_4 alkylsulfonyl, sulfinyl and C_1-C_4 alkylsulfinyl.

15. (Currently amended) ~~Use according to~~ The method of claim 1, wherein the ~~compounds~~ compound of ~~the general~~ formula **I**, ~~pharmaceutically acceptable salts and solvates thereof are~~ is selected from the group consisting of:

8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-chloro-2-methyl-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

5-fluoro-2-methyl-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

6-chloro-2-methyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-methyl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-bromo-2-methyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-bromo-2-methyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-chloro-2-methyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-methyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-methyl-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

(6-chloro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-acetonitrile;

8-oxa-1-thia-3-aza-dibenzo[e,h]azulene-2-carbaldehyde;

5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene-2-carbaldehyde;

5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene-2-carbaldehyde;

1,8-dithia-3-aza-dibenzo[e,h]azulene-2-carbaldehyde;

6-chloro-2-vinyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

(6-chloro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-acetic acid ethyl ester;

6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene-2-carboxylic acid ethyl ester;

5-fluoro-1,8-dithia-3-aza-dibenzo[e,h]azulene-2-carboxylic acid ethy ester;

5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-yl-acetic acid methyl ester;

5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-yl-acetic acid methyl ester;

2-phenyl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(4-chloro-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-pyridin-3-yl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-pyridin-4-yl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-thiophen-3-yl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(3-pyrrol-1-yl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(3-chloro-4-fluoro-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(4-tert-butyl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-pyrazin-2-yl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-trifluoromethyl-2-(4-trifluoromethyl-phenyl)-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(4-[1,3]dioxolan-2-yl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

(6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-(3,4,5-trimethoxy-phenyl)amine;

(3-methoxy-phenyl)-(6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-amine;

2-(3,5-dibromo-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(3-fluoro-4-methyl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,3-dihydro-benzofuran-5-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-p-toluyl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(4-[1,2,3]thiadiazol-4-yl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-isoxazol-5-yl-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2-methyl-thiazol-4-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(6-methyl-pyridin-3-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(6-methoxy-pyridin-3-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,6-dichloro-benzyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-trifluoromethyl-2-(4-trifluoromethyl-pyridin-3-yl)-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,6-dichloro-4-trifluoromethyl-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,4-dichloro-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-trifluoromethyl-2-(3-trifluoromethyl-phenyl)-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(5-methyl-isoxazol-3-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2-chloro-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,6-dichloro-pyridin-4-yl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-trifluoromethyl-2-(6-trifluoromethyl-pyridin-2-yl)-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-(2,4-difluoro-phenyl)-6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-pyridin-4-yl-6-trifluoromethyl-8-oxa-1-thia-3-aza-dibenzo[e,h]azulene;

5,6-dichloro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

2-pyridin-4-yl-8H-1-thia-3-aza-dibenzo[e,h]azulene;

5-methoxy-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-fluoro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

7-chloro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

7-bromo-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-chloro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-bromo-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

7-chloro-5-fluoro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-methyl-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

7-methyl-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

5-chloro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-methyl-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

6-chloro-5-fluoro-2-pyridin-4-yl-1,8-dithia-3-aza-dibenzo[e,h]azulene;

1-(2-pyridin-4-yl-1-thia-3,8-diaza-dibenzo[e,h]azulen-8-yl)-ethanone;

(8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

(5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

(5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

(1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

2-(6-chloro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-ethanol;

(6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

(5-fluoro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-methanol;

dimethyl-[2-(8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-amine;

dimethyl-[3-(8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-amine;

3-(8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-amine;

[2-(5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-dimethylamine;

[3-(5-fluoro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-dimethylamine;

[2-(5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-dimethylamine;

[3-(5-chloro-8-oxa-1-thia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-dimethylamine;

[2-(1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-dimethylamine;

[3-(1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-dimethylamine;

{3-[2-(6-chloro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-yl)-ethoxy]-propyl}-dimethylamine;

dimethyl-[2-(6-trifluoromethyl-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-amine;

[2-(5-fluoro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-dimethylamine;

dimethyl-[2-(5-fluoro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-ethyl]-dimethylamine; ~~and~~

[3-(5-fluoro-1,8-dithia-3-aza-dibenzo[e,h]azulen-2-ylmethoxy)-propyl]-dimethylamine; and

a pharmaceutically acceptable salt or solvate thereof.